<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0">
<channel>


<title>aktiencheck.de - Forum - NuCana plc ADR</title>
<link>http://www.aktiencheck.de</link>
<description>aktiencheck.de</description>
<language></language>
<copyright>aktiencheck.de</copyright>
<lastBuildDate>Sat, 18 Apr 2026 08:07:42 +0200</lastBuildDate>
<ttl>2</ttl>








<item>
<title>NuCana - Zeit zum Kaufen?</title>
<link>http://www.aktiencheck.de/forum/NuCana_Zeit_zum_Kaufen-A41DTP-t569096</link>
<guid>http://www.aktiencheck.de/forum/NuCana_Zeit_zum_Kaufen-A41DTP-t569096</guid>
<description>NuCana mögliche Übernahme durch Kyowa?, Sehr interessanter Beitrag von einem Stockwits Analysten über NuCana.

BREAKING! New Analysis on NuCana
lan Webster is an experienced finance professional with over 20 years in the field, including more than 10 years in the biopharmaceutical sector. He served as Group Financial Controller at Kyowa Kirin International plc for six years, overseeing the integration following the £230 million acquisition of Archimedes Pharma.
Recent news reports that CEO Hugh S. Griffith of NuCana is taking a leave of absence due to health issues. The board has appointed lan Webster as Interim CFO while Andrew Kay serves as Executive Chairman. This transition could be crucial for the company's future direction.
NuCana's stock surged over 150% after promising data was released on the combination therapy of NUC-7738 and Keytruda for metastatic melanoma. These developments have sparked speculation about potential acquisitions, not only by Merck but also by Kyowa Ki [&lt;a href=&#034;http://www.aktiencheck.de/forum/NuCana_Zeit_zum_Kaufen-A41DTP-t569096&#034;&gt;mehr&lt;/a&gt;]</description>
</item>

</channel>
</rss>







